251 related articles for article (PubMed ID: 23825071)
1. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin protects podocytes from damage by advanced glycation end-products.
Ruester C; Franke S; Bondeva T; Wolf G
Nephron Exp Nephrol; 2011; 117(1):e21-30. PubMed ID: 20689331
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin prevents diabetes-induced podocyte damage.
Schiffer M; Park JK; Tossidou I; Bartels J; Shushakova N; Menne J; Fliser D
Kidney Blood Press Res; 2008; 31(6):411-5. PubMed ID: 19096223
[TBL] [Abstract][Full Text] [Related]
4. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury.
Menne J; Park JK; Shushakova N; Mengel M; Meier M; Fliser D
J Am Soc Nephrol; 2007 Jul; 18(7):2046-53. PubMed ID: 17554150
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
Rüster C; Bondeva T; Franke S; Förster M; Wolf G
Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner.
Bondeva T; Wojciech S; Wolf G
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F852-70. PubMed ID: 21734098
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone-related protein induces hypertrophy in podocytes via TGF-beta(1) and p27(Kip1): implications for diabetic nephropathy.
Romero M; Ortega A; Izquierdo A; López-Luna P; Bosch RJ
Nephrol Dial Transplant; 2010 Aug; 25(8):2447-57. PubMed ID: 20200004
[TBL] [Abstract][Full Text] [Related]
8. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
9. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Jung E; Kim J; Ho Kim S; Kim S; Cho MH
Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
[TBL] [Abstract][Full Text] [Related]
10. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
11. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.
Baba M; Wada J; Eguchi J; Hashimoto I; Okada T; Yasuhara A; Shikata K; Kanwar YS; Makino H
J Am Soc Nephrol; 2005 Nov; 16(11):3222-34. PubMed ID: 16177004
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy.
Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Liu BC
Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1140-8. PubMed ID: 25921580
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
14. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
Zhang M; Liu M; Xiong M; Gong J; Tan X
J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
[TBL] [Abstract][Full Text] [Related]
15. Chronic erythropoietin treatment affects different molecular pathways of diabetic cardiomyopathy in mouse.
Shushakova N; Park JK; Menne J; Fliser D
Eur J Clin Invest; 2009 Sep; 39(9):755-60. PubMed ID: 19614950
[TBL] [Abstract][Full Text] [Related]
16. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.
Zhang L; Li R; Shi W; Liang X; Liu S; Ye Z; Yu C; Chen Y; Zhang B; Wang W; Lai Y; Ma J; Li Z; Tan X
Br J Pharmacol; 2013 Sep; 170(2):426-39. PubMed ID: 23826864
[TBL] [Abstract][Full Text] [Related]
17. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome.
Aizawa K; Takeda S; Tashiro Y; Yorozu K; Hirata M; Kanada H; Moriguchi Y; Endo K
Am J Nephrol; 2012; 36(5):419-26. PubMed ID: 23128049
[TBL] [Abstract][Full Text] [Related]
18. Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression.
Liebisch M; Bondeva T; Franke S; Daniel C; Amann K; Wolf G
Kidney Int; 2014 Jul; 86(1):103-17. PubMed ID: 24476693
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
Wang S; Li Y; Zhao J; Zhang J; Huang Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity.
Bondeva T; Wolf G
Am J Nephrol; 2009; 30(4):336-45. PubMed ID: 19590177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
